Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Year 3 Academic Weeks > A2- Interstitial Lung Disease > Flashcards

A2- Interstitial Lung Disease Flashcards

1
Q

What is intersitial space?

A

It is the liquid space between the alveolar cell wall and capillaries
It is a small space

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is IDL?

A

Interstitial Lung disease

A ‘potential space’ that is
‘widened’ in interstitial disease by influx of inflammatory and
fibrotic cells/tissue

• Its disruption leads to type 1 Respiratory Failure- hypoxia

• Some forms of ILD’s can involve
not only the interstitial space but
also alveoli and bronchioles.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How are IDLS classified?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How can you further classify
Idiopathic interstitial pneumonias?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the Suspected ILD diagnostic approach?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What do you need to ask in a detailed history?

A
  • breathlessness
    is it coming and going,
    getting worse,
    stable
    how is it impacting life (can they get dressed)
  • cough
    dry
    sputum
  • exposure
    occupation
    instruments
    damp environment
    so hobbies/interests
  • smoking
  • drug history
  • family history
  • Pmhx
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

WHat to expect o physical examination?

A

Crackles (velcro being pulling apart)

Hands

eyes

skin- rashes

Heart disease

Swelling fingers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are asbestos fibres?

A

Naturally occurring fibrous mineral silicates - good fire retardant and insulating properties. Tiny fibres that are inhaled.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Occupation wise who would be exposed to asbestos?

A

Occupational exposure: pipe fitters, plumbers, dockers, miners

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is Absbestosis?

A

A form of ILD characterised by slowly progressive pulmonary fibrosis caused by inhalation of asbestos fibres. Lungs cannot break down fibres

Immune system keeps attacking/cells release inflammatory chemicals to try and destroy fibres- fails - asbestos is a tough material

Eventually this can lead to fibrosis but often 20- 40 years after exposure - lag phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Diagnoses for Asbestosis?

A

history of enough asbestos exposure need occupational history + latency period, ILD on scan, plus exclusion of other causes of that pattern of ILD on scan (i.e. right ILD patterns need to be seen). No easy ‘test’.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Diagnoses for Asbestosis?

A

history of enough asbestos exposure need occupational history + latency period, ILD on scan, plus exclusion of other causes of that pattern of ILD on scan (i.e. right ILD patterns need to be seen). No easy ‘test’.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Tx for asbestosis?

A

was no specific treatment for asbestosis.

o Now evidence that anti fibrotic drugs may have a role (await NICE assessment).

o Avoidance of any further asbestos exposure.

o Supportive care.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

There is increased risk of Lung Cancer in smokers with asbestos exposure

TRUE OR FALSE

A

TRUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What Hypersensitivity Pneumonitis (previously aka EAA)?

A

A form of ILD that is caused by an immunologic reaction to an inhaled agent/organic antigen. E.g. bird fanciers lung

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How do you classify EAA

A

• Traditional Classification: according to onset of presentation of respiratory symptoms and amount of repeated exposure. Acute (hrs-wks), Subacute (1-4 months), chronic (>6 mths). Now probably out of date….

  • Use terms acute or inflammatory HP (may be reversible if remove exposure lungs can be ok) Vs. Chronic or Fibrotic HP (fibrosis has occurred and lungs never back to normal). Findings on CT scans permit these labels to be applied. Outcomes very different.
16
Q

Pathogenesis Hypersensitivity Pneumonitis?

A
  • Host response to exposure is not predictable. Not fully understood
  • Complex interaction: genetic predisposition, antigen, frequency/duration of exposure, co exposure with viruses?
  • Antigen exposure → specific IgG antibodies.
  • Subsequent exposure to that antigen causes immune reaction → lung inflammation
  • Some patients stay at ‘inflammation’ stage despite continued exposure other progress to fibrosis and permanent lung damage
  • Lymphocyte driven process- can see increases in blood and lung fluid after exposures Pathogenesis Hypersensitivity Pneumonitis CT image showing air trapping Lung tissue sample HP airway centred fibrosis loo
17
Q

Hypersensitivity Pneumonitis Diagnosis

A
  • Antigen exposure (history, IgG-specific antibodies)
  • Clinical (symptoms, crackles & squawks on examination)
  • Radiological (CXR, HRCT)
  • PFTs: restrictive, obstructive, or mixed pattern, reduced DLCO
  • Bronchoscopy/ Bronchoalveolar Lavage: lymphocytosis (>20%)
  • Lung Biopsy: poorly formed, non-caseating granulomas
18
Q

Hypersensitivity Pneumonitis Management:

A
  • Antigen avoidance
  • Steroids
  • Immunosuppressive therapy
  • Best Supportive care
19
Q

Causes of Hypersensitivity Pneumonitis (HP)

A

..microbes, organic material and chemical sensitisers

  • Bird Fanciers Lung (pigeons/budgies)
  • Duck Fever/Chicken lung
  • Hot tub lung (mycobacterium avium)

Occupational causes: But stays in granulomata box

  • Millers (flour)Lung
  • Mummy handlers lung (fungal spores as unwrap)
  • Wine makers lung (mould on grapes)
20
Q

What is sarcoidosis?

A

A multisystem disease of unknown cause characterised by tissue infiltration with non-caseating granulomas. In some leads to end organ damage if left untreated. Many organs can be affected

21
Q

Who are sarcoidosis most prevalent in?

A

: high in Ireland/Scandinavia,

F>M,

70+% aged

20-40 yrs at presentation

22
Q

Diagnosis of Sarcoidosis

A

: 3 Key Elements:

  • Clinical + Radiological Compatibility
  • Exclusion of other diseases
  • Non-Caseating Granulomas (NCG) from tissue biopsy
23
Q

Pathogenesis of sarcoidosis?

A
  • Need genetic susceptibility/environmental exposures/?infectious agents probably inhaled
  • Unknown trigger switches on an inflammatory process which can cause damage to organs
  • Lesions seen are Sarcoid granulomatas = are non-necrotizing
  • Circular swirl of inflammatory cells
24
Q

Staging of Sarcoidosis by CXR

A
25
Q

CT in Sarcoidosis

What does it look like

A

Typical reticulonodular shadowing on CT in sarcoidosis with enlarged lymph nodes: central pattern of disease

26
Q

Detailed diagnosis for Sarcoidosis

A
  • CXR, HRCT Thorax
  • Pulmonary Function Tests
  • Blood tests: FBC, Renal, Bone. Serum ACE:
  • Bronchoscopy: Endobronchial biopsy/Endobronchial Ultrasound (EBUS) biopsy of lymph nodes.
  • Surgical Lung Biopsy (VATS
27
Q

Management for sarcoidosis?

A
  • Observation (no treatment): if asymptomatic, non-progressive/mild disease.
  • Corticosteroids - ± Immunosuppressive Therapy
28
Q

What is Idiopathic Pulmonary Fibrosis?

A

IPF is a chronic progressive fibrotic lung disease of ‘unknown cause’. ‘An error in patients ability to ‘heal’ their lungs’ after day to day environmental interaction. Must have right ILD pattern and right story to make this diagnosis

29
Q

Prevalance of IPF

A
  • Age 50-70, M>F, >90% sporadic
  • Familial <7% cases –younger, Auto. Dom, Variable penetrance
30
Q

IPF Diagnosis

A

→ Progressive Pulmonary symptoms/clinical findings + no identifiable cause ± Restrictive Physiology + UIP (on HRCT Thorax ± Biopsy)

31
Q

IPF management?

A
  • Anti-fibrotic therapy (Nintedanib, Pirfenidone): UK if FVC 50-80% predicted.
  • Lung Transplantation in selected cases (1% only reach this).
  • Best supportive care (O2 assessment, Pulmonary Rehab, Dietician, Palliative/symptom Care, Psychology).

Acute exacerbations → Respiratory Failure: High in-hospital mortality

32
Q

What is Non-Specific Interstitial Pneumonia (NSIP)?

A

A chronic IIP that is characterized by a homogeneous appearance of dense interstitial fibrosis mild to moderate chronic interstitial inflammation.

  • idiopathic, but most commonly associated with CTD (Scleroderma, Sjogren’s, myositis), drugs, HIV
33
Q

Management for NSIP

A
  • Observation (with supportive care) - Corticosteroids ± immunosuppressive therapy - iv methylprednisolone & cyclophosphamide - Refractory disease is sometimes treated with rituximab (CD20 inhibitor).

In contrast to UIP/IPF, NSIP has a more favourable prognosis: 70%+ alive at 10 years with Rx

34
Q

What is the approach for ILD care

A
35
Q

Treatment options in ILD may be about to change:

How?

A

Anti fibrotic drugs are going to be considered by the National Institute of Clinical Excellence (NICE) in near future, for wider indications than IPF.

Any fibrotic ILD that progresses despite usual treatments may become a candidate for anti fibrotic drugs

Year 3 Academic Weeks (40 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions